LL-37 Cream Investigated for Healing and Infection Control in Diabetic Foot Ulcers

Diabetic foot ulcer (DFU) is a severe and common complication of diabetes, affecting a global prevalence of 6.3% of individuals with the condition. These ulcers are notoriously challenging to treat, often leading to poor outcomes including infection, amputation, and significant morbidity. Current management strategies, while crucial, often fall short, highlighting a critical need for innovative therapeutic approaches that can enhance wound healing and effectively control infection. LL-37, a naturally occurring human antimicrobial peptide, has emerged as a promising candidate for its potential to address these complex issues.

The primary objective of this study was to determine if LL-37 cream could significantly improve the healing trajectory of diabetic foot ulcers compared to conventional standard care. Researchers hypothesized that treatment with LL-37 cream would lead to a measurable reduction in bacterial load within the wounds, thereby mitigating infection. Furthermore, it was anticipated that the cream would modulate the inflammatory environment, evidenced by a decrease in pro-inflammatory markers such as IL-1α and TNF-α. > The study aimed to demonstrate a quantifiable acceleration in the healing rate of diabetic foot ulcers, potentially leading to faster wound closure and improved patient outcomes. While the trial's completion date was January 2020, specific quantitative results detailing bacterial reduction, inflammatory marker changes, or precise healing rate improvements have not yet been publicly released or published.